Providing active pharmaceutical ingredient to ANDA defendant not induced infringement
The Federal Circuit has reversed a grant of summary judgment for induced infringement against a defendant who provided the active pharmaceutical ingredient to an ANDA defendant seeking to bring a generic onto the market
The ruling came today in Shire v Amneal Pharmaceuticals, a Hatch-Waxman case involving four patents (US Patents 7,105,786, 7,655,630, 7,659,253 and 7,662,787) covering an amphetamine that is less susceptible to abuse, LDX dimesylate. Shire holds the patents and markets LDX...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.